Importantly, testing also found an SLC4A4-ROS1 fusion (Fig 1). On December 6, 2016, the patient started therapy with entrectinib. Within 2 weeks of treatment, the patient experienced myalgias and fatigue, which abated with short-dose interruptions, and the patient resumed the highly active lifestyle he had at baseline, with a normal performance status and no loss of appetite or weight. He had a minor response (a reduction of 12.5%; stable disease per RECIST v1.1) and was considering definitive resection of the primary pancreatic mass, as well as metastasectomy of the liver disease. The patient experienced progressive disease in June 2017.